var data={"title":"Recombinant human parathyroid hormone (1-84): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Recombinant human parathyroid hormone (1-84): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/197601?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=recombinant-human-parathyroid-hormone-1-84-patient-drug-information\" class=\"drug drug_patient\">see &quot;Recombinant human parathyroid hormone (1-84): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26965150\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Potential risk of osteosarcoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In male and female rats, parathyroid hormone caused an increase in the incidence of osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was dependent on parathyroid hormone dose and treatment duration. This effect was observed at parathyroid hormone exposure levels ranging from 3 to 71 times the exposure levels in humans receiving a 100 mcg dose of Natpara. These data could not exclude a risk to humans.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of a potential risk of osteosarcoma, use Natpara only in patients who cannot be well-controlled on calcium and active forms of vitamin D alone and for whom the potential benefits are considered to outweigh this potential risk.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid use of Natpara in patients who are at increased baseline risk for osteosarcoma such as patients with Paget disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, patients with hereditary disorders predisposing  to osteosarcoma or patients with a prior history of external beam or implant radiation therapy involving the skeleton.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of osteosarcoma, Natpara is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Natpara REMS Program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736278\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Natpara</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26965153\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Parathyroid Hormone Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258034\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoparathyroidism:</b> SubQ: <b>Note:</b> Prior to initiation of therapy, confirm that the serum calcium concentration is &gt;7.5 mg/dL and the 25-hydroxyvitamin D stores are sufficient (correct if insufficient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 50 mcg once daily.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustment:</i> <b>Note:</b> Active forms of vitamin D and calcium supplementation may require adjustment during parathyroid hormone therapy based on albumin-corrected serum calcium concentrations; consult parathyroid hormone product labeling for more information. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum calcium (albumin-corrected) cannot be maintained &gt;8 mg/dL without an active form of vitamin D and/or calcium supplementation: Increase the parathyroid hormone dose in increments of 25 mcg/day every 4 weeks; maximum daily dose: 100 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum calcium (albumin-corrected) repeatedly &gt;9 mg/dL after discontinuation of active forms of vitamin D and calcium supplementation decreased to a dose sufficient to meet daily needs: May decrease the parathyroid hormone dose to a minimum of 25 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> Use the lowest dose required to prevent both hypocalcemia and hypercalciuria while maintaining albumin-corrected serum calcium concentrations at the lower half of the normal range (ie, between 8 and 9 mg/dL) without the need for active forms of vitamin D and with calcium supplementation sufficient to meet the patient&rsquo;s daily requirements.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Discontinuation or interruption of therapy:</i> An abrupt interruption or discontinuation may result in severe hypocalcemia; resume treatment with or increase the dose of an active form of vitamin D and calcium supplementation (if indicated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose:</i> Administer parathyroid hormone as soon as reasonably feasible; additional calcium should be administered in the event of hypocalcemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258035\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dosing should start at the lower end of dosing range and titrate to response due to possible increased incidence of hepatic, renal, or cardiac impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258036\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (CrCl &ge;30 mL/minute): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (CrCl &lt;30 mL/minute): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258037\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736279\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cartridge, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Natpara: 25 mcg (1 ea); 50 mcg (1 ea); 75 mcg (1 ea); 100 mcg (1 ea) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736277\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27106784\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Natpara: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM433356.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giqvD4BTWErdB/9MEOOOcemw==&amp;TOPIC_ID=99571\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM433356.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258039\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously into the thigh (alternate thighs each day) using the provided Q-Cliq pen. Follow instructions provided with the medication cartridges and the Q-Cliq pen to prepare the injection device for use. One Q-Cliq pen may be used for up to 2 years, with changing the reconstituted cartridge every 2 weeks. Patients and caregivers who will administer parathyroid hormone should receive appropriate training and instruction by a trained health care professional prior to first use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26965155\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypoparathyroidism: </b> Adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Because of the potential risk of osteosarcoma, recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone; has not been studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute postsurgical hypoparathyroidism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27159032\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (31%), headache (25%), hypoesthesia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (27%), hypercalcemia (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (12%), vomiting (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hypercalciuria (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Immunogenicity (6% to 16%; drug efficacy not affected)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral pain (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Inhibited conversion of vitamin d3 to 25-hydroxy-d3 (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Upper abdominal pain (7%), facial numbness (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Osteosarcoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Neck pain (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (8%), sinusitis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Drug toxicity (risk when used concomitantly with digoxin and other drugs known to increase serum calcium)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26965156\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258015\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Severe hypercalcemia has been reported; the risk is highest during initiation of therapy and dose escalation. Monitor serum calcium concentrations and patients for signs and symptoms of hypercalcemia. Treat hypercalcemia as needed and consider temporary discontinuation or a reduction in dose if severe hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Severe hypocalcemia has been reported and can occur at any time during therapy; the risk is highest when a dose is missed or when parathyroid hormone therapy is withheld or abruptly discontinued. Monitor serum calcium concentrations and patients for signs and symptoms of hypocalcemia. In patients who must have therapy interrupted or discontinued, resume treatment with or increase the dose of an active form of vitamin D and/or calcium supplements to prevent severe hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteosarcoma: <b>[US Boxed Warning]: In animal studies, parathyroid hormone has been associated with an increase in osteosarcoma; risk was dependent on both dose and duration. Avoid use in patients with an increased risk of osteosarcoma (including Paget disease, prior external beam or implant radiation therapy involving the skeleton, unexplained elevation of alkaline phosphatase, patients with open epiphyses, patients with hereditary disorders predisposing to osteosarcoma). Treatment should only be used in patients who cannot be well controlled on calcium supplements and active forms of vitamin D alone.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calcium supplementation: In patients receiving calcium supplementation, maintain the same dose of calcium at initiation of parathyroid hormone therapy. Calcium supplementation may require titration during parathyroid hormone therapy based on albumin-corrected serum calcium concentrations; consult parathyroid hormone product labeling for more information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin D: In patients receiving active forms of vitamin D, reduce the dose of active vitamin D by 50% at initiation of parathyroid hormone therapy if serum calcium is &gt;7.5 mg/dL. Active forms of vitamin D may require titration during parathyroid hormone therapy based on albumin-corrected serum calcium concentrations; consult parathyroid hormone product labeling for more information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004245\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27004242\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=99571&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alendronate: May diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Parathyroid Hormone may enhance the adverse/toxic effect of Cardiac Glycosides. More specifically, Parathyroid Hormone-related hypercalcemia may predispose to digitalis toxicity. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258011\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258012\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258014\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if parathyroid hormone from this preparation is excreted into breast milk. According to the manufacturer, the decision breast-feed should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258040\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Total serum calcium (albumin-corrected) prior to therapy initiation, within 3 to 7 days following initiation or dosage adjustments until maintenance dose has been achieved, and periodically thereafter; urinary calcium excretion (after maintenance dose is achieved); signs and symptoms of hypo- and hypercalcemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258020\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exogenous parathyroid hormone; parathyroid hormone raises serum calcium concentrations by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption, and by increasing bone turnover, which releases calcium into the circulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27258022\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect: 10 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &gt;24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 5.35 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic; cleavage by cathepsins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 53%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 5 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Renal (primarily by glomerular filtration)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326120\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cartridge</b> (Natpara Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (1): $5,608.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (1): $5,608.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (1): $5,608.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $5,608.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27000851\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Preotact (DE, ES, GB, GR, HU, IT, MT, PL, PT, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Natpara (parathyroid hormone) [prescribing information]. Lexington, MA: NPS Pharmaceuticals; July 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 99571 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26965150\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27736278\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26965153\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F27258034\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F27258035\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F27258036\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F27258037\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27736279\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F27736277\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F27106784\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27258039\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26965155\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27159032\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26965156\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F27258015\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27004245\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27004242\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F27258011\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27258012\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F27258014\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27258040\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F27258020\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F27258022\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28326120\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27000851\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/99571|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=recombinant-human-parathyroid-hormone-1-84-patient-drug-information\" class=\"drug drug_patient\">Recombinant human parathyroid hormone (1-84): Patient drug information</a></li></ul></div></div>","javascript":null}